标题：卡培他滨维持化疗在转移性直肠癌一线化疗后应用的控制效果及预后

      作者：焦移乐 1，邵志勇 1，马骏 2    1.陕西中医药大学第二附属医院普外科，陕西 咸阳 712000；2.西安高新医院肛肠科，陕西 西安 710077

      卷次： 2020年31卷4期

      【摘要】 目的 探讨卡培他滨维持化疗在转移性直肠癌一线化疗后应用的控制效果及其对患者预后的影响，为临床治疗提供指导。方法 选择陕西中医药大学第二附属医院2017年1月至2018年5月接诊的60例转移性直肠癌并接受一线化疗的患者作为研究对象，根据简单随机分组法将患者均分为对照组和观察组各30例。对照组一线化疗后进行随访观察，观察组一线化疗后使用卡培他滨维持化疗，化疗3周后，比较两组患者的中位无进展生存期(PFS)、控制效果和一线化疗时不良反应情况，同时比较观察组患者在维持治疗时与一线化疗时的不良反应情况。结果 观察组患者的 PFS为(12.04±2.77) 个月，明显长于对照组的(8.11±1.45)个月，差异有统计学意义(P<0.05)；观察组患者的控制率为66.67%，明显高于对照组的36.67%，差异有统计学意义(P<0.05)；两组患者一线化疗时的各种不良反应比较差异无统计学意义(P>0.05)；观察组患者维持化疗时的恶心、呕吐、腹泻的发生率分别为16.67%、16.67%、6.67%，明显低于一线化疗时的50.00%、46.67%、43.33%，差异均有统计学意义(P<0.05)。结论 转移性直肠癌一线化疗后给予卡培他滨维持化疗，可以延长患者的中位无进展生存期，提高生存率，明显改善预后，值得临床推广。
      【关键词】 移性；直肠癌；一线化疗；卡培他滨；效果；预后
      【中图分类号】 R735.3+7 【文献标识码】 A 【文章编号】 1003—6350（2020）04—0418—04

Control effect and prognosis of capecitabine maintenance chemotherapy after first-line chemotherapy formetastatic rectal cancer.
JIAO Yi-le 1, SHAO Zhi-yong 1, MA Jun 2. 1. Department of General Surgery, the SecondAffiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang 712000, Shaanxi, CHINA; 2.Department of Anorectal Surgery, the High-tech Hospital of Xi'an, Xi'an 710077, Shaanxi, CHINA
【Abstract】 Objective To investigate the control effect of capecitabine maintenance chemotherapy afterfirst-line chemotherapy for metastatic rectal cancer and its effect on prognosis of patients, so as to provide guidance forclinical treatment. Methods A total of 60 patients with metastatic rectal cancer, who received first-line chemotherapyfrom January 2017 to May 2018 in the Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medi-cine, were selected as the study subjects. According to random number table method, the patients were divided into thecontrol group and observation group, with 30 patients in each group. The patients of the control group were followed upafter first-line chemotherapy, and the patients of the observation group was performed with capecitabine maintenancechemotherapy after first-line chemotherapy. After 3 weeks of chemotherapy, the median progression free survival (PFS),control effect, and adverse reactions during the first-line chemotherapy were compared between the two groups, and theadverse reactions during the maintenance treatment and the first-line chemotherapy in the observation group were com-pared. Results The PFS of the observation group was (12.04±2.77) months, which was significantly longer than (8.11±1.45) months of the control group (P<0.05); the control rate of the observation group was 66.67%, which was significant-ly higher than 36.67% of the control group (P<0.05); the adverse reactions of the first-line chemotherapy of the twogroups were compared, the difference was not statistically significant (P>0.05); the incidence of nausea, vomiting and di-arrhea in the observation group was 16.67%, 16.67%, 6.67%, respectively, which were significantly lower than corre-sponding 50.00%, 46.67% and 43.33% in the first-line chemotherapy (all P<0.05). Conclusion After first-line chemo-therapy for metastatic rectal cancer, capecitabine maintenance chemotherapy can prolong median progression-free surviv-al, improve survival rate and significantly improve prognosis, which is worthy of clinical promotion.
      【Key words】 Metastasis; Rectal cancer; First-line chemotherapy; Capecitabine; Effect; Prognosis